Arrowstreet Capital Limited Partnership Has $192.11 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Arrowstreet Capital Limited Partnership boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 79.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 369,285 shares of the medical research company’s stock after buying an additional 162,962 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 0.10% of Thermo Fisher Scientific worth $192,113,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. American Money Management LLC increased its stake in shares of Thermo Fisher Scientific by 0.4% in the fourth quarter. American Money Management LLC now owns 5,386 shares of the medical research company’s stock worth $2,802,000 after purchasing an additional 24 shares in the last quarter. Allianz SE purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $7,814,000. Allstate Corp boosted its stake in shares of Thermo Fisher Scientific by 3,264.2% during the fourth quarter. Allstate Corp now owns 11,371 shares of the medical research company’s stock valued at $5,916,000 after purchasing an additional 11,033 shares during the period. RiverFront Investment Group LLC increased its position in shares of Thermo Fisher Scientific by 27.7% in the fourth quarter. RiverFront Investment Group LLC now owns 484 shares of the medical research company’s stock valued at $252,000 after acquiring an additional 105 shares during the period. Finally, DnB Asset Management AS raised its position in Thermo Fisher Scientific by 1.4% during the 4th quarter. DnB Asset Management AS now owns 201,281 shares of the medical research company’s stock valued at $104,712,000 after purchasing an additional 2,810 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. UBS Group lifted their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Raymond James reissued an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Bank of America lowered their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Morgan Stanley raised their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $653.23.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 2.3 %

NYSE TMO opened at $499.75 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a 50-day simple moving average of $541.60 and a 200-day simple moving average of $551.84. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The firm has a market capitalization of $188.53 billion, a PE ratio of 30.23, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.34%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.